文献速递前列腺癌

阿帕他胺、阿比特龙与恩扎卢胺联合方案治疗mHSPC的真实世界比较效果

Comparative effectiveness of apalutamide-, abiraterone-, and enzalutamide-based doublets in mHSPC.
PubMed 文献 · BJU Int · 2026-09-01

该研究系统检索并汇总了17项回顾性真实世界研究、共18 626例mHSPC患者,比较以阿帕他胺(APA)、阿比特龙(ABI)或恩扎卢胺(ENZA)为基础的双联方案。结果显示APA方案在OS和PSA深度缓解方面优于ABI,ABI因不良事件停药率低于APA,ABI与ENZA疗效和安全性相当。

要点

  • 真实世界中APA方案较ABI方案与更好OS及更深PSA缓解相关。
  • ABI方案因不良事件停药率低于APA,ENZA与APA无显著差异。
  • ABI与ENZA疗效和安全性相当,支持个体化选择ARPI。

核心结论

  • 真实世界数据显示APA为基础的双联方案较ABI方案疗效更优,而ABI和ENZA方案因不良事件停药率更低。
  • ABI与ENZA疗效和安全性相当,支持mHSPC中个体化选择ARPI。

研究设计与样本

  • 系统检索于2025年9月22日在PubMed、Embase和Cochrane Library进行,纳入报告真实世界数据的回顾性研究。
  • 共纳入17项回顾性研究,合计18 626例接受APA、ABI或ENZA联合ADT治疗的mHSPC患者。
  • 采用逆方差随机效应模型计算汇总风险比(HR)和比值比(OR)。

主要发现

  • 与ABI相比,APA与改善OS相关(HR 1.27;95%CI 1.09-1.47;P=0.002)。
  • APA较ABI与更高PSA90(OR 0.70;95%CI 0.54-0.91;P=0.019)和PSA<0.2 ng/mL(OR 0.49;95%CI 0.25-0.95;P=0.039)相关。
  • APA较ABI与改善去势抵抗性前列腺癌(CRPC)相关(HR 1.40;95%CI 1.05-1.88;P=0.023)。
  • APA较ENZA有更高PSA90缓解率(OR 0.67;95%CI 0.5-0.9;P=0.017)。
  • 因不良事件停药ABI低于APA(OR 0.56;95%CI 0.37-0.86;P=0.029),ENZA与APA无显著差异(P=0.10)。

临床怎么用

  • 在mHSPC真实世界决策中,可参考APA方案在OS和PSA深度缓解方面的相对优势。
  • 对不良事件停药风险关注较高者,可考虑ABI或ENZA方案。
  • ABI与ENZA疗效和安全性相当,支持根据患者具体情况个体化选择ARPI。

局限性

  • 纳入研究均为回顾性真实世界研究,可能存在选择偏倚和混杂。
  • 缺乏ARPI为基础双联方案之间的直接比较随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved from androgen-deprivation therapy (ADT) alone to combination therapy with androgen receptor pathway inhibitors. Although apalutamide (APA), abiraterone (ABI), and enzalutamide (ENZA) improve outcomes when added to ADT, direct comparative trials between androgen receptor pathway inhibitor-based doublets are lacking. METHODS: Our systematic search was conducted on 22 September 2025, in PubMed, Embase, and the Cochrane Library databases. Studies including patients with mHSPC treated with APA, ABI, or ENZA plus ADT were eligible if they contained real-world data and reported at least one outcome: overall survival (OS), PSA50, PSA90, PSA ≤0.2 ng/mL, time to castration-resistant prostate cancer, biochemical progression-free survival, grade ≥3 adverse events, or treatment discontinuation (TDC). Pooled hazard ratios (HRs) and odds ratios (ORs) were calculated using inverse variance random-effects models. KEY FINDINGS AND LIMITATIONS: In total, 17 retrospective studies comprising 18 626 patients were included. Compared with ABI, APA was associated with improved OS (HR 1.27; 95% confidence interval [CI] 1.09-1.47; P = 0.002), PSA90 (OR 0.70; 95% CI 0.54-0.91; P = 0.019), PSA <0.2 ng/mL (OR 0.49; 95% CI 0.25-0.95; P = 0.039), and castration-resistant prostate cancer (HR 1.40; 95% CI 1.05-1.88; P = 0.023). APA also demonstrated higher PSA90 response rates than ENZA (OR 0.67; 95% CI 0.5-0.9; P = 0.017). TDC due to adverse events was lower with ABI than with APA (OR 0.56; 95% CI 0.37-0.86; P = 0.029), with no significant difference between ENZA and APA (P = 0.10). CONCLUSIONS AND CLINICAL IMPLICATIONS: In real-world settings, APA-based doublets were associated with more favourable efficacy outcomes with ABI, whereas ABI- and ENZA-based regimens were associated with lower TDC rates. ABI and ENZA demonstrated comparable efficacy and safety profiles, supporting individualized ARPI selection in mHSPC.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Valikovics AK, Bacsó D, Samaien N, et al. Comparative effectiveness of apalutamide-, abiraterone-, and enzalutamide-based doublets in mHSPC. BJU Int. 2026. PMID: 42678311. doi:10.1111/bju.70438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。